GDTC vs. DERM, TCRX, ARTV, PROC, RANI, ATOS, CRBP, CLYM, ZURA, and ANIX
Should you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include Journey Medical (DERM), TScan Therapeutics (TCRX), Artiva Biotherapeutics (ARTV), Procaps Group (PROC), Rani Therapeutics (RANI), Atossa Therapeutics (ATOS), Corbus Pharmaceuticals (CRBP), Climb Bio (CLYM), Zura Bio (ZURA), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry.
CytoMed Therapeutics vs.
Journey Medical (NASDAQ:DERM) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, community ranking, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.
CytoMed Therapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -31.74%. CytoMed Therapeutics' return on equity of 0.00% beat Journey Medical's return on equity.
Journey Medical presently has a consensus target price of $9.67, suggesting a potential upside of 86.26%. CytoMed Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 78.57%. Given Journey Medical's stronger consensus rating and higher possible upside, equities analysts clearly believe Journey Medical is more favorable than CytoMed Therapeutics.
CytoMed Therapeutics has lower revenue, but higher earnings than Journey Medical.
In the previous week, Journey Medical had 2 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 2 mentions for Journey Medical and 0 mentions for CytoMed Therapeutics. Journey Medical's average media sentiment score of 0.97 beat CytoMed Therapeutics' score of 0.00 indicating that Journey Medical is being referred to more favorably in the media.
7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 13.2% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Journey Medical received 1 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users.
Journey Medical has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.92, meaning that its stock price is 192% less volatile than the S&P 500.
Summary
Journey Medical beats CytoMed Therapeutics on 11 of the 15 factors compared between the two stocks.
Get CytoMed Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CytoMed Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GDTC) was last updated on 2/22/2025 by MarketBeat.com Staff
